Lung Cancer Tests

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20130225442A1
SERIAL NO

13880103

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods for the diagnosis of lung cancer and more specifically, non-small cell lung cancer are described. An assortment of biomarkers with diagnostic or prognostic value for non-small cell lung cancer (NSCLC) are used to establish a multi-analyte serum test capable of diagnosing patients with lung cancer. A first method assesses an elevated level of expression of one or more nucleic acids, a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide. An alternative method includes (a) determining whether or not a patient has NSCLC versus a non-NSCLC lung cancer, and (b) classifying the patient as susceptible to specific treatments if the patient has a NSCLC profile and classifying the patient as not susceptible to a specific treatment if the patient does not have a NSCLC profile.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
RUSH UNIVERSITY MEDICAL CENTER1653 WEST CONGRESS PARKWAY CHICAGO IL 60612

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Borgia, Jeffrey A Chicago, US 6 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation